Fulminant type 1 diabetes has been described as a subtype of type 1 diabetes characterized by accelerated progression and without the presence of islet-associated autoantibody. Thus far, several reports have documented the occurrence of type 1 diabetes, including the fulminant type, after anti-programmed cell death protein 1 (PD-1) antibody treatment for malignant tumors 1 . T cells are deactivated by inhibitory signals, such as those produced by PD-1 and the ligand PD-L1 2 , and PD-1 inhibition by anti-PD-1 antibody probably triggers an autoimmune phenomenon through the reduction of the immune checkpoint function of T cells.
Previously, we reported a case of fulminant type 1 diabetes that developed after the treatment of a malignant melanoma with the anti-PD-1 antibody, nivolumab 3 . A 63-year-old Japanese woman with melanoma received eight courses of anti-PD-1 immunotherapy, which was discontinued 6 weeks before the onset of fulminant type 1 diabetes. Laboratory data at the onset of fulminant diabetes were as follows: plasma glucose 661 mg/ dL, pH 6.95, total ketone body 8,477.5 lmol/L, glycated hemoglobin 8.6%, serum C-peptide 0.08 ng/mL, elastase 1 1100 ng/dL and CRP 1.89 mg/dL.
We recently evaluated the human leukocyte antigen type in this patient and found that she had an HLA-DRB1*09:01 genotype, which is a susceptible human leukocyte antigen type in Japanese type 1 diabetes patients.
Although previous reports have documented similar cases 1, 2 , we believe no report has described the changes in intrinsic insulin secretion capacity; that is, C-peptide level, after the onset of fulminant type 1 diabetes caused by anti-PD-1 antibody treatment.
The present patient was followed up without using anti-PD-1 antibody after the onset of fulminant type 1 diabetes, because the treatment was ineffective against malignant melanoma.
As shown in the Figure 1 , the serum Cpeptide level was relatively higher (range 0.12-0.37 ng/mL) than that seen in typical fulminant type 1 diabetes 4 . Furthermore, even 10 months after the onset, C-peptide was still detected (0.17 ng/mL). During this time-course, the patient's glycated hemoglobin ranged 7.0-8.6%, postprandial plasma glucose level 145-348 mg/dL and insulin dose 46-48 units/day.
A reason for the residual b-cell function in the present case might be the effect of intensive insulin therapy, especially at the onset of fulminant type 1 diabetes. Nevertheless, we suspect that not only the intensive insulin therapy, but also the discontinuation of anti-PD-1 antibody treatment, might have prevented the b-cell destruction after the onset of fulminant type 1 diabetes caused by anti-PD-1 antibody treatment.
If the prognosis will be worsened by the discontinuation of the anti-PD-1 antibody treatment, we might have to continue the treatment throughout the patient's life. However, if there is an alternative treatment choice for the malignancy, the discontinuation of anti-PD-1 antibody treatment might be the one of choice, because this could help preserve pancreatic b-cell function in the patient.
We should monitor changes in the intrinsic insulin secretion capacity; that is, C-peptide level, of patients with 'anti-PD-1 antibody-induced' fulminant type 1 diabetes, and discuss whether treatment discontinuation can be considered by accumulating and analyzing reports of similar cases henceforth. 
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